Cargando…

The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus faecalis

Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium frequently found in the gastrointestinal tract, oral cavity, and periodontal tissue. Although it is considered a commensal, it can cause bacteremia, endocarditis, endodontic infections, and urinary tract infections. Because an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dongwook, Im, Jintaek, Na, Hongjun, Ryu, Sangryeol, Yun, Cheol-Heui, Han, Seung Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927925/
https://www.ncbi.nlm.nih.gov/pubmed/31921055
http://dx.doi.org/10.3389/fmicb.2019.02877
_version_ 1783482368261095424
author Lee, Dongwook
Im, Jintaek
Na, Hongjun
Ryu, Sangryeol
Yun, Cheol-Heui
Han, Seung Hyun
author_facet Lee, Dongwook
Im, Jintaek
Na, Hongjun
Ryu, Sangryeol
Yun, Cheol-Heui
Han, Seung Hyun
author_sort Lee, Dongwook
collection PubMed
description Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium frequently found in the gastrointestinal tract, oral cavity, and periodontal tissue. Although it is considered a commensal, it can cause bacteremia, endocarditis, endodontic infections, and urinary tract infections. Because antibiotics are cytotoxic not only to pathogens, but also to health-beneficial commensals, phage therapy has emerged as an alternative strategy to specifically control pathogenic bacteria with minimal damage to the normal flora. In this study, we isolated a novel phage, Enterococcus phage vB_EfaS_HEf13 (phage HEf13), with broad lytic activity against 12 strains of E. faecalis among the three laboratory strains and 14 clinical isolates of E. faecalis evaluated. Transmission electron microscopy showed that phage HEf13 has morphological characteristics of the family Siphoviridae. Phage HEf13 was stable at a wide range of temperature (4–60°C) and showed tolerance to acid or alkaline (pH 3–12) growth conditions. Phage HEf13 had a short latent period (25 min) with a large burst size (approximately 352 virions per infected cell). The lytic activity of phage HEf13 at various multiplicities of infection consistently inhibited the growth of diverse clinical isolates of E. faecalis without any lysogenic process. Moreover, phage HEf13 showed an effective lytic activity against E. faecalis on human dentin ex vivo infection model. Whole genome analysis demonstrated that the phage HEf13 genome contains 57,811 bp of double-stranded DNA with a GC content of 40.1% and 95 predicted open reading frames (ORFs). Annotated functional ORFs were mainly classified into four groups: DNA replication/packaging/regulation, phage structure, host cell lysis, and additional functions such as RNA transcription. Comparative genomic analysis demonstrated that phage HEf13 is a novel phage that belongs to the Sap6virus lineage. Furthermore, the results of multiple sequence alignment showed that polymorphism of phage infection protein of E. faecalis (PIP(EF)) contributes to determine the host specificity of phage HEf13 against various E. faecalis strains. Collectively, these results suggest that phage HEf13 has characteristics of a lytic phage, and is a potential therapeutic agent for treatment or prevention of E. faecalis-associated infectious diseases.
format Online
Article
Text
id pubmed-6927925
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69279252020-01-09 The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus faecalis Lee, Dongwook Im, Jintaek Na, Hongjun Ryu, Sangryeol Yun, Cheol-Heui Han, Seung Hyun Front Microbiol Microbiology Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium frequently found in the gastrointestinal tract, oral cavity, and periodontal tissue. Although it is considered a commensal, it can cause bacteremia, endocarditis, endodontic infections, and urinary tract infections. Because antibiotics are cytotoxic not only to pathogens, but also to health-beneficial commensals, phage therapy has emerged as an alternative strategy to specifically control pathogenic bacteria with minimal damage to the normal flora. In this study, we isolated a novel phage, Enterococcus phage vB_EfaS_HEf13 (phage HEf13), with broad lytic activity against 12 strains of E. faecalis among the three laboratory strains and 14 clinical isolates of E. faecalis evaluated. Transmission electron microscopy showed that phage HEf13 has morphological characteristics of the family Siphoviridae. Phage HEf13 was stable at a wide range of temperature (4–60°C) and showed tolerance to acid or alkaline (pH 3–12) growth conditions. Phage HEf13 had a short latent period (25 min) with a large burst size (approximately 352 virions per infected cell). The lytic activity of phage HEf13 at various multiplicities of infection consistently inhibited the growth of diverse clinical isolates of E. faecalis without any lysogenic process. Moreover, phage HEf13 showed an effective lytic activity against E. faecalis on human dentin ex vivo infection model. Whole genome analysis demonstrated that the phage HEf13 genome contains 57,811 bp of double-stranded DNA with a GC content of 40.1% and 95 predicted open reading frames (ORFs). Annotated functional ORFs were mainly classified into four groups: DNA replication/packaging/regulation, phage structure, host cell lysis, and additional functions such as RNA transcription. Comparative genomic analysis demonstrated that phage HEf13 is a novel phage that belongs to the Sap6virus lineage. Furthermore, the results of multiple sequence alignment showed that polymorphism of phage infection protein of E. faecalis (PIP(EF)) contributes to determine the host specificity of phage HEf13 against various E. faecalis strains. Collectively, these results suggest that phage HEf13 has characteristics of a lytic phage, and is a potential therapeutic agent for treatment or prevention of E. faecalis-associated infectious diseases. Frontiers Media S.A. 2019-12-17 /pmc/articles/PMC6927925/ /pubmed/31921055 http://dx.doi.org/10.3389/fmicb.2019.02877 Text en Copyright © 2019 Lee, Im, Na, Ryu, Yun and Han. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Lee, Dongwook
Im, Jintaek
Na, Hongjun
Ryu, Sangryeol
Yun, Cheol-Heui
Han, Seung Hyun
The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus faecalis
title The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus faecalis
title_full The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus faecalis
title_fullStr The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus faecalis
title_full_unstemmed The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus faecalis
title_short The Novel Enterococcus Phage vB_EfaS_HEf13 Has Broad Lytic Activity Against Clinical Isolates of Enterococcus faecalis
title_sort novel enterococcus phage vb_efas_hef13 has broad lytic activity against clinical isolates of enterococcus faecalis
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927925/
https://www.ncbi.nlm.nih.gov/pubmed/31921055
http://dx.doi.org/10.3389/fmicb.2019.02877
work_keys_str_mv AT leedongwook thenovelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT imjintaek thenovelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT nahongjun thenovelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT ryusangryeol thenovelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT yuncheolheui thenovelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT hanseunghyun thenovelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT leedongwook novelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT imjintaek novelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT nahongjun novelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT ryusangryeol novelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT yuncheolheui novelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis
AT hanseunghyun novelenterococcusphagevbefashef13hasbroadlyticactivityagainstclinicalisolatesofenterococcusfaecalis